IL311863A - Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods - Google Patents

Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods

Info

Publication number
IL311863A
IL311863A IL311863A IL31186324A IL311863A IL 311863 A IL311863 A IL 311863A IL 311863 A IL311863 A IL 311863A IL 31186324 A IL31186324 A IL 31186324A IL 311863 A IL311863 A IL 311863A
Authority
IL
Israel
Prior art keywords
combination
kras
inhibitor
carcinoma
irinotecan
Prior art date
Application number
IL311863A
Other languages
English (en)
Hebrew (he)
Inventor
Jill Hallin
James Gail Christensen
Vickie Bowcut
Peter Olson
Original Assignee
Mirati Therapeutics Inc
Jill Hallin
James Gail Christensen
Vickie Bowcut
Peter Olson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc, Jill Hallin, James Gail Christensen, Vickie Bowcut, Peter Olson filed Critical Mirati Therapeutics Inc
Publication of IL311863A publication Critical patent/IL311863A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL311863A 2021-10-05 2022-10-04 Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods IL311863A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (1)

Publication Number Publication Date
IL311863A true IL311863A (en) 2024-06-01

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311863A IL311863A (en) 2021-10-05 2022-10-04 Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods

Country Status (10)

Country Link
US (1) US20250249003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537137A (cg-RX-API-DMAC7.html)
KR (1) KR20240073115A (cg-RX-API-DMAC7.html)
CN (1) CN118354794A (cg-RX-API-DMAC7.html)
AU (1) AU2022361219A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233571A1 (cg-RX-API-DMAC7.html)
IL (1) IL311863A (cg-RX-API-DMAC7.html)
MX (1) MX2024004214A (cg-RX-API-DMAC7.html)
WO (1) WO2023059600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
JP2024537137A (ja) 2024-10-10
EP4412720A4 (en) 2025-08-13
MX2024004214A (es) 2024-07-29
WO2023059600A1 (en) 2023-04-13
CA3233571A1 (en) 2023-04-13
CN118354794A (zh) 2024-07-16
KR20240073115A (ko) 2024-05-24
EP4412720A1 (en) 2024-08-14
US20250249003A1 (en) 2025-08-07
AU2022361219A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
IL274601B1 (en) Kras g12c inhibitors
FI3849537T3 (fi) Yhdistelmäterapioita
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2025000630A5 (cg-RX-API-DMAC7.html)
IL315645A (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
CN102612365B (zh) 用于强化dna损伤剂的检查点激酶1抑制剂
IL314486A (en) Quinazoline compounds inhibit PAN-KRAS
JP2024537139A5 (cg-RX-API-DMAC7.html)
JP2024537140A5 (cg-RX-API-DMAC7.html)
JP2024537137A5 (cg-RX-API-DMAC7.html)
EP3110509B1 (en) Treating cancer with a combination comprising dinaciclib
US9155726B2 (en) Method of treatment using checkpoint kinase 1 inhibitors
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2023540809A5 (cg-RX-API-DMAC7.html)
WO2023059600A1 (en) Combinations of kras g12d inhibitors with irinotecan and related methods of treatment
JP2025512999A5 (cg-RX-API-DMAC7.html)
IL315648A (en) Combination therapy of SOS1 inhibitor and MEK inhibitor
US20110034498A1 (en) Dosing regimens for the treatment of cancer
IL319808A (en) Combined treatments
CN120693329A (zh) 2-(4-(4-(氨基甲基)-1-氧代-1,2-二氢酞嗪-6-基)-1-甲基-1h-吡唑-5-基)-4-氯-6-环丙氧基-3-氟苄腈的晶形
CN120693331A (zh) 2-(4-(4-(氨基甲基)-1-氧代-1,2-二氢酞嗪-6-基)-1-甲基-1h-吡唑-5-基)-4-氯-6-环丙氧基-3-氟苄腈的晶形
WO2023019095A2 (en) Momelotinib combination therapy
JP2025513802A5 (cg-RX-API-DMAC7.html)